Eintrag weiter verarbeiten
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Journal of Clinical Oncology, 27, 2009, 25, S. 4124-4129 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Ay, Cihan Vormittag, Rainer Dunkler, Daniela Simanek, Ralph Chiriac, Alexandru-Laurentiu Drach, Johannes Quehenberger, Peter Wagner, Oswald Zielinski, Christoph Pabinger, Ingrid Ay, Cihan Vormittag, Rainer Dunkler, Daniela Simanek, Ralph Chiriac, Alexandru-Laurentiu Drach, Johannes Quehenberger, Peter Wagner, Oswald Zielinski, Christoph Pabinger, Ingrid |
|---|---|
| author |
Ay, Cihan Vormittag, Rainer Dunkler, Daniela Simanek, Ralph Chiriac, Alexandru-Laurentiu Drach, Johannes Quehenberger, Peter Wagner, Oswald Zielinski, Christoph Pabinger, Ingrid |
| spellingShingle |
Ay, Cihan Vormittag, Rainer Dunkler, Daniela Simanek, Ralph Chiriac, Alexandru-Laurentiu Drach, Johannes Quehenberger, Peter Wagner, Oswald Zielinski, Christoph Pabinger, Ingrid Journal of Clinical Oncology D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study Cancer Research Oncology |
| author_sort |
ay, cihan |
| spelling |
Ay, Cihan Vormittag, Rainer Dunkler, Daniela Simanek, Ralph Chiriac, Alexandru-Laurentiu Drach, Johannes Quehenberger, Peter Wagner, Oswald Zielinski, Christoph Pabinger, Ingrid 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2008.21.7752 <jats:sec><jats:title>Purpose</jats:title><jats:p> Venous thromboembolism (VTE) is a well-recognized complication of cancer. Laboratory parameters might be useful to assess the VTE risk in patients with cancer. The aim of this study was to investigate D-dimer and prothrombin fragment 1 + 2 (F 1 + 2), which reflect activation of blood coagulation and fibrinolysis, for prediction of cancer-associated VTE. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> In a prospective, observational, cohort study of 821 patients with newly diagnosed cancer or progression of disease who did not recently receive chemotherapy, radiotherapy, or surgery were enrolled and followed for a median of 501 days (interquartile range, 255 to 731 days). The malignancies in these patients were as follows: breast (n = 132), lung (n = 119), stomach (n = 35), lower gastrointestinal tract (n = 106), pancreas (n = 46), kidney (n = 22), and prostate (n = 101) cancers; high-grade glioma (n = 102); malignant lymphoma (n = 94); multiple myeloma (n = 17); and other tumor types (n = 47). The study end point was occurrence of objectively confirmed symptomatic or fatal VTE. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> VTE occurred in 62 patients (7.6%). The cutoff level for elevated D-dimer and elevated F 1 + 2 was set at the 75th percentile of the total study population. In multivariable analysis that included elevated D-dimer, elevated F 1 + 2, age, sex, surgery, chemotherapy, and radiotherapy, the hazard ratios (HRs) of VTE in patients with elevated D-dimer (HR, 1.8; 95% CI, 1.0 to 3.2; P = .048) and elevated F 1 + 2 (HR, 2.0; 95% CI, 1.2 to 3.6; P = .015) were statistically significantly increased. The cumulative probability of developing VTE after 6 months was highest in patients with both elevated D-dimer and elevated F 1 + 2 (15.2%) compared with patients with nonelevated D-dimer and nonelevated F 1 + 2 (5.0%; P < .001). </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> High D-dimer and F 1 + 2 levels independently predict occurrence of VTE in patients with cancer. </jats:p></jats:sec> D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2008.21.7752 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4yMS43NzUy |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4yMS43NzUy |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
American Society of Clinical Oncology (ASCO), 2009 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2009 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
ay2009ddimerandprothrombinfragment12predictvenousthromboembolisminpatientswithcancerresultsfromtheviennacancerandthrombosisstudy |
| publishDateSort |
2009 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_unstemmed |
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_full |
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_fullStr |
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_full_unstemmed |
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_short |
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_sort |
d-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the vienna cancer and thrombosis study |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2008.21.7752 |
| publishDate |
2009 |
| physical |
4124-4129 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p> Venous thromboembolism (VTE) is a well-recognized complication of cancer. Laboratory parameters might be useful to assess the VTE risk in patients with cancer. The aim of this study was to investigate D-dimer and prothrombin fragment 1 + 2 (F 1 + 2), which reflect activation of blood coagulation and fibrinolysis, for prediction of cancer-associated VTE. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> In a prospective, observational, cohort study of 821 patients with newly diagnosed cancer or progression of disease who did not recently receive chemotherapy, radiotherapy, or surgery were enrolled and followed for a median of 501 days (interquartile range, 255 to 731 days). The malignancies in these patients were as follows: breast (n = 132), lung (n = 119), stomach (n = 35), lower gastrointestinal tract (n = 106), pancreas (n = 46), kidney (n = 22), and prostate (n = 101) cancers; high-grade glioma (n = 102); malignant lymphoma (n = 94); multiple myeloma (n = 17); and other tumor types (n = 47). The study end point was occurrence of objectively confirmed symptomatic or fatal VTE. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> VTE occurred in 62 patients (7.6%). The cutoff level for elevated D-dimer and elevated F 1 + 2 was set at the 75th percentile of the total study population. In multivariable analysis that included elevated D-dimer, elevated F 1 + 2, age, sex, surgery, chemotherapy, and radiotherapy, the hazard ratios (HRs) of VTE in patients with elevated D-dimer (HR, 1.8; 95% CI, 1.0 to 3.2; P = .048) and elevated F 1 + 2 (HR, 2.0; 95% CI, 1.2 to 3.6; P = .015) were statistically significantly increased. The cumulative probability of developing VTE after 6 months was highest in patients with both elevated D-dimer and elevated F 1 + 2 (15.2%) compared with patients with nonelevated D-dimer and nonelevated F 1 + 2 (5.0%; P < .001). </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> High D-dimer and F 1 + 2 levels independently predict occurrence of VTE in patients with cancer. </jats:p></jats:sec> |
| container_issue |
25 |
| container_start_page |
4124 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
27 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348329583050758 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:09:15.258Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=D-Dimer+and+Prothrombin+Fragment+1+%2B+2+Predict+Venous+Thromboembolism+in+Patients+With+Cancer%3A+Results+From+the+Vienna+Cancer+and+Thrombosis+Study&rft.date=2009-09-01&genre=article&issn=1527-7755&volume=27&issue=25&spage=4124&epage=4129&pages=4124-4129&jtitle=Journal+of+Clinical+Oncology&atitle=D-Dimer+and+Prothrombin+Fragment+1+%2B+2+Predict+Venous+Thromboembolism+in+Patients+With+Cancer%3A+Results+From+the+Vienna+Cancer+and+Thrombosis+Study&aulast=Pabinger&aufirst=Ingrid&rft_id=info%3Adoi%2F10.1200%2Fjco.2008.21.7752&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348329583050758 |
| author | Ay, Cihan, Vormittag, Rainer, Dunkler, Daniela, Simanek, Ralph, Chiriac, Alexandru-Laurentiu, Drach, Johannes, Quehenberger, Peter, Wagner, Oswald, Zielinski, Christoph, Pabinger, Ingrid |
| author_facet | Ay, Cihan, Vormittag, Rainer, Dunkler, Daniela, Simanek, Ralph, Chiriac, Alexandru-Laurentiu, Drach, Johannes, Quehenberger, Peter, Wagner, Oswald, Zielinski, Christoph, Pabinger, Ingrid, Ay, Cihan, Vormittag, Rainer, Dunkler, Daniela, Simanek, Ralph, Chiriac, Alexandru-Laurentiu, Drach, Johannes, Quehenberger, Peter, Wagner, Oswald, Zielinski, Christoph, Pabinger, Ingrid |
| author_sort | ay, cihan |
| container_issue | 25 |
| container_start_page | 4124 |
| container_title | Journal of Clinical Oncology |
| container_volume | 27 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p> Venous thromboembolism (VTE) is a well-recognized complication of cancer. Laboratory parameters might be useful to assess the VTE risk in patients with cancer. The aim of this study was to investigate D-dimer and prothrombin fragment 1 + 2 (F 1 + 2), which reflect activation of blood coagulation and fibrinolysis, for prediction of cancer-associated VTE. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> In a prospective, observational, cohort study of 821 patients with newly diagnosed cancer or progression of disease who did not recently receive chemotherapy, radiotherapy, or surgery were enrolled and followed for a median of 501 days (interquartile range, 255 to 731 days). The malignancies in these patients were as follows: breast (n = 132), lung (n = 119), stomach (n = 35), lower gastrointestinal tract (n = 106), pancreas (n = 46), kidney (n = 22), and prostate (n = 101) cancers; high-grade glioma (n = 102); malignant lymphoma (n = 94); multiple myeloma (n = 17); and other tumor types (n = 47). The study end point was occurrence of objectively confirmed symptomatic or fatal VTE. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> VTE occurred in 62 patients (7.6%). The cutoff level for elevated D-dimer and elevated F 1 + 2 was set at the 75th percentile of the total study population. In multivariable analysis that included elevated D-dimer, elevated F 1 + 2, age, sex, surgery, chemotherapy, and radiotherapy, the hazard ratios (HRs) of VTE in patients with elevated D-dimer (HR, 1.8; 95% CI, 1.0 to 3.2; P = .048) and elevated F 1 + 2 (HR, 2.0; 95% CI, 1.2 to 3.6; P = .015) were statistically significantly increased. The cumulative probability of developing VTE after 6 months was highest in patients with both elevated D-dimer and elevated F 1 + 2 (15.2%) compared with patients with nonelevated D-dimer and nonelevated F 1 + 2 (5.0%; P < .001). </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> High D-dimer and F 1 + 2 levels independently predict occurrence of VTE in patients with cancer. </jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2008.21.7752 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOC4yMS43NzUy |
| imprint | American Society of Clinical Oncology (ASCO), 2009 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2009 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T18:09:15.258Z |
| match_str | ay2009ddimerandprothrombinfragment12predictvenousthromboembolisminpatientswithcancerresultsfromtheviennacancerandthrombosisstudy |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 4124-4129 |
| publishDate | 2009 |
| publishDateSort | 2009 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Ay, Cihan Vormittag, Rainer Dunkler, Daniela Simanek, Ralph Chiriac, Alexandru-Laurentiu Drach, Johannes Quehenberger, Peter Wagner, Oswald Zielinski, Christoph Pabinger, Ingrid 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2008.21.7752 <jats:sec><jats:title>Purpose</jats:title><jats:p> Venous thromboembolism (VTE) is a well-recognized complication of cancer. Laboratory parameters might be useful to assess the VTE risk in patients with cancer. The aim of this study was to investigate D-dimer and prothrombin fragment 1 + 2 (F 1 + 2), which reflect activation of blood coagulation and fibrinolysis, for prediction of cancer-associated VTE. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> In a prospective, observational, cohort study of 821 patients with newly diagnosed cancer or progression of disease who did not recently receive chemotherapy, radiotherapy, or surgery were enrolled and followed for a median of 501 days (interquartile range, 255 to 731 days). The malignancies in these patients were as follows: breast (n = 132), lung (n = 119), stomach (n = 35), lower gastrointestinal tract (n = 106), pancreas (n = 46), kidney (n = 22), and prostate (n = 101) cancers; high-grade glioma (n = 102); malignant lymphoma (n = 94); multiple myeloma (n = 17); and other tumor types (n = 47). The study end point was occurrence of objectively confirmed symptomatic or fatal VTE. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> VTE occurred in 62 patients (7.6%). The cutoff level for elevated D-dimer and elevated F 1 + 2 was set at the 75th percentile of the total study population. In multivariable analysis that included elevated D-dimer, elevated F 1 + 2, age, sex, surgery, chemotherapy, and radiotherapy, the hazard ratios (HRs) of VTE in patients with elevated D-dimer (HR, 1.8; 95% CI, 1.0 to 3.2; P = .048) and elevated F 1 + 2 (HR, 2.0; 95% CI, 1.2 to 3.6; P = .015) were statistically significantly increased. The cumulative probability of developing VTE after 6 months was highest in patients with both elevated D-dimer and elevated F 1 + 2 (15.2%) compared with patients with nonelevated D-dimer and nonelevated F 1 + 2 (5.0%; P < .001). </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> High D-dimer and F 1 + 2 levels independently predict occurrence of VTE in patients with cancer. </jats:p></jats:sec> D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study Journal of Clinical Oncology |
| spellingShingle | Ay, Cihan, Vormittag, Rainer, Dunkler, Daniela, Simanek, Ralph, Chiriac, Alexandru-Laurentiu, Drach, Johannes, Quehenberger, Peter, Wagner, Oswald, Zielinski, Christoph, Pabinger, Ingrid, Journal of Clinical Oncology, D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study, Cancer Research, Oncology |
| title | D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_full | D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_fullStr | D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_full_unstemmed | D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_short | D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| title_sort | d-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the vienna cancer and thrombosis study |
| title_unstemmed | D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2008.21.7752 |